IPOPLUS

₹867.1

▲ +15.6 +1.83%

18 Jun 2026

NSE Listed

Natco Pharma Limited (NATCOPHARM)

Volume: 12,63,551Avg Vol 1W: 9,57,553.4Avg Vol 1M: 7,19,128.0552W Range:₹789₹1,226.8
NSE BSE
₹867.1▲ 1.83%
Key Ratios
Updated 9h ago
Market Cap₹15,472 Cr
Current Price₹867.1
Previous Close₹851.5
High / Low (52w)₹1,226.8 / ₹789
Volume12,63,551
Avg Vol (1W)9,57,553.4
Avg Vol (1M)7,19,128.05
Stock P/E80.69
Book Value₹515.15
Dividend Yield0.6%
ROE15.4%
ROA12.4%
Revenue (TTM)₹4,784 Cr
Revenue Growth10.8%
Profit Margin34.8%
Total Debt₹0 Cr
Shares Outstanding18 Cr
Face Value₹2
EPS (TTM)₹14.96
P/B1.68
Debt / Equity0.08
50 DMA₹1,036.84
200 DMA₹913.55
Day change+1.83%
Price Chart
₹867.1▼ 0.50% · 1Y
₹1175₹7932.3Cr
2025-06-17
2026-05-11

20-day avg volume: 7.2L shares

Pros
  • Healthy return on equity of 15.4%.
  • Company is almost debt-free.
Cons
  • Stock trades at a high P/E of 81.
Quarterly Results
MetricJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue₹1,363 Cr₹1,371 Cr₹475 Cr₹1,221 Cr₹1,329 Cr₹1,363 Cr₹647 Cr₹739 Cr
EBITDA₹809 Cr₹822 Cr₹168 Cr₹516 Cr₹575 Cr₹627 Cr₹171 Cr₹155 Cr
Net Profit₹669 Cr₹677 Cr₹133 Cr₹407 Cr₹481 Cr₹518 Cr₹152 Cr₹268 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹2,022 Cr₹2,156 Cr₹2,044 Cr₹2,812 Cr₹4,127 Cr₹4,784 Cr
EBITDA₹590 Cr₹593 Cr₹220 Cr₹876 Cr₹1,693 Cr₹2,315 Cr
Net Profit₹461 Cr₹441 Cr₹170 Cr₹715 Cr₹1,388 Cr₹1,885 Cr
EPS——————
Balance Sheet
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹4,588 Cr₹4,792 Cr₹5,109 Cr₹5,657 Cr₹6,906 Cr₹8,631 Cr
Total Liabilities₹803 Cr₹669 Cr₹846 Cr₹784 Cr₹1,053 Cr₹1,019 Cr
Equity₹3,785 Cr₹4,123 Cr₹4,264 Cr₹4,874 Cr₹5,853 Cr₹7,612 Cr
Total Debt₹1 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Cash Flow
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹525 Cr₹429 Cr₹95 Cr₹1,027 Cr₹1,498 Cr₹2,069 Cr
Investing₹-167 Cr₹-103 Cr₹-5 Cr₹-477 Cr₹-1,033 Cr₹-1,414 Cr
Financing₹-251 Cr₹-186 Cr₹35 Cr₹-363 Cr₹-247 Cr₹-211 Cr
Free Cash Flow₹525 Cr₹429 Cr₹95 Cr₹1,027 Cr₹1,498 Cr₹2,069 Cr

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search